Back to top
more

Bio-Rad Laboratories, Inc. (BIO)

(Delayed Data from NYSE)

$369.97 USD

369.97
73,434

-5.37 (-1.43%)

Updated Jan 24, 2020 03:59 PM ET

Add to portfolio

4-Sell       4  

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1
2
3
4
5
S&P
Strong Buy
Buy
Hold
Sell
Strong Sell
500
24.66%
17.94%
9.57%
5.30%
2.19%
10.75%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

D Value | A Growth | B Momentum | B VGM

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

View All Zacks #1 Ranked Stocks

Trades from $1

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Zacks News

Zacks Equity Research

Bio-Rad Gains on New Product Portfolio Despite Currency Woes

Bio-Rad's (BIO) new product uptake in the United States is appreciative with the recent 510(k) clearance of the IH-Reader 24.

OMCL BIO HAE NUVA

Zacks Equity Research

Bio-Rad's Blood Typing Market Growth Strong on New Products

Bio-Rad's (BIO) new product acceptance in the United States is a positive with the recent 510(k) clearance of the IH-Reader 24.

BIO RMD HAE EYE

Zacks Equity Research

Bio-Rad (Bio) Q3 Earnings Beat Estimates on All-Line Growth

Growing strength in many of Bio-Rad's (Bio) key product lines across major geographic regions buoys investors' optimism on the stock.

TMO RMD BIO EW

Zacks Equity Research

Bio-Rad Laboratories (BIO) Q3 Earnings Beat Estimates

Bio-Rad (BIO) delivered earnings and revenue surprises of 18.38% and -0.14%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

BIO

Zacks Equity Research

Bio-Rad Laboratories (BIO) Earnings Expected to Grow: Should You Buy?

Bio-Rad (BIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

BIO

Zacks Equity Research

LabCorp (LH) Names Two Leaders for Major Business Wings

Managenment believes that under Schechter's term with Paul and John's crucial support, LabCorp (LH) looks well-positioned to grow and thrive in times ahead.

BIO DGX LH CRL

Zacks Equity Research

Bruker To Buy Freiberg Instruments' Magnettech EPR Business

The Freiberg Instruments' Magnettech EPR business acquisition is expected to boost Bruker's (BRKR) BioSpin business by complementing its existing range of EPR offerings.

BRKR PKI BIO A

Zacks Equity Research

Abbott (ABT) Gets FDA Nod for New Troponin-I Blood Test

The regulatory go-ahead for Abbott's (ABT) ARCHITECT STAT High Sensitivity Troponin-I blood test is a major stride forward in its commitment for detecting patients suspected of having a heart attack.

ABT BIO BAX BSX

Zacks Equity Research

Bio-Rad (BIO) Up 8.8% Since Last Earnings Report: Can It Continue?

Bio-Rad (BIO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

BIO

Zacks Equity Research

Here's Why You Should Retain Bio-Rad (BIO) Stock for Now

Investors' confidence continues to be high on solid prospects of Bio-Rad (BIO).

MDT BIO BAX AMED

Zacks Equity Research

PRGO vs. BIO: Which Stock Is the Better Value Option?

PRGO vs. BIO: Which Stock Is the Better Value Option?

PRGO BIO

Zacks Equity Research

Bio-Rad (Bio) Q2 Earnings Beat Estimates, Margins Expand

We are upbeat about Bio-Rad's (BIO) year-over-year revenue growth within the Clinical Diagnostics segment in Q2.

ISRG SYK BAX BIO

Zacks Equity Research

Bio-Rad Laboratories (BIO) Surpasses Q2 Earnings and Revenue Estimates

Bio-Rad (BIO) delivered earnings and revenue surprises of 12.95% and 1.66%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

BIO

Zacks Equity Research

Analysts Estimate Bio-Rad Laboratories (BIO) to Report a Decline in Earnings: What to Look Out for

Bio-Rad (BIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

BIO

Trina Mukherjee

IVD Market Sustains Momentum: 3 Stocks in Focus

In-vitro Diagnostics has successfully proven itself to be the best diagnostic procedures. So, investors can add stocks from this space to their watchlist.

RHHBY ABT TMO BIO BDX

Zacks Equity Research

ABT or BIO: Which Stock Has Better Potential Right Now?

Abbott (ABT) scores higher than Bio-Rad (BIO) in terms of valuation and one-year price performance.

ABT PEN BIO NUVA

Zacks Equity Research

Here's Why You Should Invest in CONMED (CNMD) Stock Now

CONMED (CNMD) continues to benefit from robust international sales, broad product portfolio and persistent focus on R&D.

OXFD HAE BIO CNMD

Zacks Equity Research

Luminex (LMNX) Presents ARIES MRSA Assay to FDA for Clearance

Luminex (LMNX) submits the ARIES MRSA assay to the FDA for clearance. The company's ARIES system will get a substantial boost once the FDA clearance is through.

OXFD LMNX HAE BIO

Zacks Equity Research

Bio-Rad (BIO) Down 6.9% Since Last Earnings Report: Can It Rebound?

Bio-Rad (BIO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

BIO

Zacks Equity Research

Here's Why You Should Retain Bio-Rad (BIO) Stock For Now

Bio-Rad (BIO) continues to witness high investor confidence on strength in the Life Sciences segment.

CERN BRKR PEN BIO

Zacks Equity Research

Bio-Rad (BIO) Q1 Earnings Beat Estimates, Margins Expand

Bio-Rad (BIO) witnesses revenue growth at the Life Sciences segment in Q1 on strength in cell biology, droplet Digital PCR and other product lines.

SYK BIO CNMD XRAY

Zacks Equity Research

Bio-Rad Laboratories (BIO) Q1 Earnings and Revenues Beat Estimates

Bio-Rad (BIO) delivered earnings and revenue surprises of 47.32% and 0.94%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

BIO

Zacks Equity Research

Will Life Sciences Sales Boost Bio-Rad's (BIO) Q1 Earnings?

Within the Life Sciences segment, high investment in several geographies along with product launches and new technologies is resulting in a strong upside for Bio-Rad (BIO).

BIO XLRN NTGN UMRX

Zacks Equity Research

Analysts Estimate Bio-Rad Laboratories (BIO) to Report a Decline in Earnings: What to Look Out for

Bio-Rad (BIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

BIO

Zacks Equity Research

CONMED (CNMD) Beats on Q1 Earnings, Raises '19 Guidance

Higher revenues, solid segmental performance and strong adjusted gross margins benefit CONMED's (CNMD) Q1 earnings. However, high long-term debt remains a concern.

BIO ICUI CNMD XRAY